CellTrend diagnostic test

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

The CellTrend Diagnostic Test is a commercial ME/CFS diagnostic immunoassay created by CellTrend, a German biotechnology company, and Professor Doctor Carmen Scheibenbogen. Cell-Trend bases its test on the theory that a subset of 20-30% of all patients suffering from ME/CFS have developed elevated levels of three auto-antibodies, i.e., auto-antibodies against the b2-adrenergic receptor, auto-antibodies against the muscarinic cholinergic receptor 3 (M3) and auto-antibodies against the muscarinic cholinergic receptor 4 (M4). The CellTrend Diagnostic Test immunoassay is a biochemical test that measures the presence of these three auto-antibodies.[1]

Notable studies[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. http://www.celltrend.de/cfs-diagnostics.html
  2. Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, K; Meisel, C; Reinke, P; Volk, H; Fluge, Ø; Mella, O; Scheibenbogen, C (2016), "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome", Brain, behavior, and immunity, 52: 32-39, doi:10.1016/j.bbi.2015.09.013